The fall of crypto, and the permanent ascent of Substack and the ‘wordcels’

First there was Covid. There was the suspense of the possibility of the world coming to an end, and then the sigh of relief when it didn’t. And then the euphoria and exhilaration of the stock market, tech/start-up, and crypto surge that followed. The 2021 crypto surge was like a proletariat revolution of the masses… Continue reading The fall of crypto, and the permanent ascent of Substack and the ‘wordcels’

Tirzepatide and Semaglutide (Mounjaro, Wegovy) are probably not worth the money

In this post I argue that Tirzepatide and Semaglutide (also known as Mounjaro, Wegovy) are probably not worth it for therapeutic purposes. The small increase of expected life expectancy by treating mild or moderate obesity is not justified by the high, recurring costs of these drugs. On the other hand, if one desires to lose… Continue reading Tirzepatide and Semaglutide (Mounjaro, Wegovy) are probably not worth the money

Right again about Trump (so far)

Imagine waking up to the trending hashtags on Twitter “#trumparrest”, #trumpindictment”, or “Indictment Day”. Your heart races or sinks…it must be related to the FBI raid of Mar-a-Lago, Jan 6th, or something to do with Russia? Or taxes? You’re thinking “this is it…it’s happening!” You hurriedly click the hashtag on the sidebar only to see… Continue reading Right again about Trump (so far)

SVB failure: the limitations of moral hazard, and the difficulty of assessing risk

I saw this viral article by Arnold Kling, Moral Hazard is widely misunderstood. He argues that bailouts allow bankers to be reckless with impunity (heads they win, tails you lose, so to speak): At this point, if I obtain some more funds from depositors , I can go to Las Vegas and hope I get… Continue reading SVB failure: the limitations of moral hazard, and the difficulty of assessing risk